Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
AssigneesKøbenhavns Universitet, Cancer Research Technology Limited
InventorsHenrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
Claims6
A monoclonal antibody secreted by the hybridoma deposited at the European Collection of Cell Cultures (ECACC) on Sep. 19, 2006, under accession number STHM1 06092102 or a humanized antibody corresponding thereto.
A monoclonal antibody secreted by the hybridoma deposited at the European Collection of Cell Cultures (ECACC) on Sep. 19, 2006, under accession number STHM2 06092101 or a humanized antibody corresponding thereto.
Dependencies are inferred from the claim text.